Clinical trial
A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without…
NCT00001564 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001564 |
|---|---|
| Title | A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas |
| Official title | A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ewing's Sarcoma, Rhabdomyosarcoma |
| Intervention type | Drug |
| Interventions | EF-1 Peptide, EF-2 Peptide, PXFK Peptide, E7 Peptide, IL-2, IL-4, GM-CSF, CD40 Ligand |
| Enrollment | 30 |
| Start date | Dec 23, 1996 |
| Primary completion | Oct 25, 2007 |
| Completion | Oct 25, 2007 |
| First posted | Nov 4, 1999 |
| Last update posted | Nov 29, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: